Vol. 5 No. 3 (2025)
Reimbursement Reviews

Venetoclax (Venclexta)

decorative image of the issue cover

Published March 27, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Venetoclax (Venclexta), 10 mg, 50 mg, and 100 mg oral tablets.
  • Indication: In combination with obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia.